These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

634 related items for PubMed ID: 15878520

  • 1. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, Pautke C, Horch HH.
    J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
    [Abstract] [Full Text] [Related]

  • 2. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
    Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR.
    Cancer Res; 1994 Jun 01; 54(11):2900-7. PubMed ID: 8187075
    [Abstract] [Full Text] [Related]

  • 3. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M.
    Cancer Res; 1993 Jun 01; 53(11):2513-21. PubMed ID: 8388317
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
    Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Späthe K, Dettmar P, Höfler H, Jänicke F, Schmitt M, Graeff H.
    Br J Cancer; 1999 Apr 01; 79(11-12):1746-51. PubMed ID: 10206287
    [Abstract] [Full Text] [Related]

  • 5. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H.
    Cancer Res; 1994 May 15; 54(10):2527-30. PubMed ID: 8168072
    [Abstract] [Full Text] [Related]

  • 6. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.
    Cancer Res; 2002 Aug 15; 62(16):4617-22. PubMed ID: 12183417
    [Abstract] [Full Text] [Related]

  • 7. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 15; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 8. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
    Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS.
    Cancer; 1997 Mar 01; 79(5):878-83. PubMed ID: 9041148
    [Abstract] [Full Text] [Related]

  • 9. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
    Nekarda H, Schlegel P, Schmitt M, Stark M, Mueller JD, Fink U, Siewert JR.
    Clin Cancer Res; 1998 Jul 01; 4(7):1755-63. PubMed ID: 9676852
    [Abstract] [Full Text] [Related]

  • 10. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
    Kobayashi H, Fujishiro S, Terao T.
    Cancer Res; 1994 Dec 15; 54(24):6539-48. PubMed ID: 7987854
    [Abstract] [Full Text] [Related]

  • 11. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
    Pedersen H, Grøndahl-Hansen J, Francis D, Osterlind K, Hansen HH, Danø K, Brünner N.
    Cancer Res; 1994 Jan 01; 54(1):120-3. PubMed ID: 8261432
    [Abstract] [Full Text] [Related]

  • 12. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep FC, Span PN, Schmitt M, Magdolen V.
    Int J Mol Med; 2008 Feb 01; 21(2):251-9. PubMed ID: 18204793
    [Abstract] [Full Text] [Related]

  • 13. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA, Leaper DJ, Hayter JP, Dickenson AJ.
    Br J Oral Maxillofac Surg; 2007 Dec 01; 45(8):623-7. PubMed ID: 17590247
    [Abstract] [Full Text] [Related]

  • 14. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H, Brünner N, Francis D, Osterlind K, Rønne E, Hansen HH, Danø K, Grøndahl-Hansen J.
    Cancer Res; 1994 Sep 01; 54(17):4671-5. PubMed ID: 8062262
    [Abstract] [Full Text] [Related]

  • 15. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 16. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
    de Witte JH, Sweep CG, Klijn JG, Grebenschikov N, Peters HA, Look MP, van Tienoven TH, Heuvel JJ, van Putten WL, Benraad TJ, Foekens JA.
    Br J Cancer; 1999 Mar 01; 79(7-8):1190-8. PubMed ID: 10098758
    [Abstract] [Full Text] [Related]

  • 17. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
    Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J.
    Anticancer Res; 2000 Mar 01; 20(5C):3975-81. PubMed ID: 11268487
    [Abstract] [Full Text] [Related]

  • 18. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM, Han DM, Yu ZK, Fan EZ, Li Y.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb 01; 38(1):39-42. PubMed ID: 12778766
    [Abstract] [Full Text] [Related]

  • 19. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
    Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M.
    Thromb Haemost; 2004 Mar 01; 91(3):450-6. PubMed ID: 14983219
    [Abstract] [Full Text] [Related]

  • 20. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
    Gandolfo GM, Conti L, Vercillo M.
    Anticancer Res; 1996 Mar 01; 16(4B):2155-9. PubMed ID: 8694536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.